US Liver Cancer Therapeutics Market Report 2022 to 2030

US Liver Cancer Therapeutics Market Analysis

$ 3999

The US liver cancer therapeutics market is projected to grow from $1.2 Bn in 2022 to $3.9 Bn by 2030, registering a CAGR of 15.6% during the forecast period of 2022-30. The market for liver cancer therapeutics in the US is driven by factors such as the increasing prevalence of liver cancer, the growing demand for effective treatment options, and advancements in technology and drug development. In addition, the increasing use of combination therapies, the development of targeted therapies, and the focus on personalized medicine are also contributing to the growth of this market. The major players operating in the US liver cancer therapeutics market include pharmaceutical companies such as Bristol-Myers Squibb, Bayer Healthcare, Pfizer Inc., Eisai Co., Ltd., and F. Hoffmann-La Roche AG.

ID: IN10USPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Shivam Zalke

Buy Now

US Liver Cancer Therapeutics Market Executive Summary

According to projections, the US market for therapies for liver cancer would increase from $1.2 billion in 2022 to $3.9 billion in 2030, recording a CAGR of 15.6% during the forecast period of 2022–30.

The market for liver cancer therapies in the US is divided into categories depending on the kind of treatment used, such as surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The most often utilized types of treatment for liver cancer among them are chemotherapy and targeted therapy.

The US market for therapies for liver cancer is also subject to a number of laws, rules, and regulations, including those governing healthcare and reimbursement, as well as FDA guidelines and approvals. It is anticipated that regulatory control and scrutiny would rise as the market for liver cancer therapies expands, necessitating more adherence to stringent standards and laws on the part of pharmaceutical companies and healthcare providers.

us liver cancer therapeutics market analysis

Market Dynamics

Growth Drivers

The increasing prevalence of liver cancer, rising research, and development expenditures for the creation of novel treatments, and government programs to raise cancer awareness are the main factors influencing the market growth. Globally, approximately 905,677 new cases of liver cancer were diagnosed in 2020, with a projected increase to 1.16 million cases by 2030. Because of this, the market under study is anticipated to grow as demand for efficient and cutting-edge liver cancer therapeutics rises over time. Several risk factors that contribute to liver cancer were made more widely available to the population as a result of the change in the way of life. The risk factors, which also are anticipated to boost the liver cancer therapeutics market's growth over the forecast period, include type 2 diabetes, hepatitis, metabolic disorders, excessive body weight, alcohol consumption, and smoking.

Competitive Landscape

Global Key Players

Some of the key players in the US liver cancer therapeutics market include:

Bayer AG
Bristol-Myers Squibb
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Taiho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited.

Local Key Players

Exelixis, Inc. - Alameda, California
Array BioPharma Inc. - Boulder, Colorado
Delcath Systems, Inc. - Queensbury, New York
Ipsen Biopharmaceuticals, Inc. - Cambridge, Massachusetts
Nektar Therapeutics - San Francisco, California
Onyx Pharmaceuticals, Inc. - San Francisco, California
SillaJen Biotherapeutics, Inc. - San Francisco, California
Spring Bank Pharmaceuticals, Inc. - Hopkinton, Massachusetts
Tarveda Therapeutics, Inc. - Watertown, Massachusetts
Urovant Sciences, Inc. - Irvine, California

Healthcare Policies and Regulatory Landscape

Many healthcare regulations and legal restrictions apply to the US market for liver cancer treatments. The following are some of the main laws and rules that affect the market:

FDA approval: Before being marketed and sold in the US, all medications and treatment modalities for liver cancer must have FDA clearance. The FDA evaluates clinical trial data to establish the efficacy and safety of medications and liver cancer treatment modalities.
Medicare Coverage: Medicare is a government health insurance program that is available to Americans 65 and older as well as certain younger persons with disabilities. Chemotherapy and radiation therapy are two liver cancer therapies that Medicare will pay for.
The Affordable Care Act (ACA) was passed into law by the federal government in 2010. The bill intends to provide access to reasonably priced healthcare and raise the quality of healthcare in the US. The ACA contains clauses requiring insurance providers to pay for specific preventative services, such as liver cancer screenings.
National Cancer Institute (NCI): The NCI is a government organization that carries out and funds studies on cancer diagnosis, treatment, and prevention. The organization also works to create new liver cancer therapies and treatments while funding research into the disease.
The Cancer Moonshot Initiative was established in 2016 with the goal of accelerating cancer research and enhancing cancer patient outcomes. The program involves money for the study of liver cancer and the creation of fresh techniques to treat the condition.

Overall, the FDA clearance process, Medicare coverage, the Affordable Care Act, the National Cancer Institute, and the Cancer Moonshot Program are important healthcare regulations that influence the US market for liver cancer medicines. In addition to ensuring that research and development efforts continue to enhance the field, these laws and regulations also work to guarantee that patients have access to safe and efficient liver cancer therapies.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.